Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹4,001Cr
Rev Gr TTM
Revenue Growth TTM
-8.04%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

LXCHEM
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | -17.0 | -3.6 | 0.0 | 6.1 | 8.4 | -1.5 | 18.2 | 13.3 | -10.4 | -3.5 | -9.3 | -8.6 |
| 672 | 652 | 613 | 642 | 702 | 647 | 697 | 712 | 651 | 662 | 663 | 669 |
Operating Profit Operating ProfitCr |
| 7.9 | 10.6 | 6.0 | 7.5 | 11.4 | 9.9 | 9.7 | 9.5 | 8.3 | 4.4 | 5.3 | 7.0 |
Other Income Other IncomeCr | 7 | 4 | 8 | 5 | 8 | 12 | 7 | 6 | 1 | 6 | 4 | 3 |
Interest Expense Interest ExpenseCr | -1 | 5 | 2 | 1 | -1 | 3 | 8 | 2 | 7 | 5 | 6 | 7 |
Depreciation DepreciationCr | 23 | 21 | 28 | 28 | 31 | 26 | 27 | 31 | 40 | 17 | 20 | 20 |
| 43 | 56 | 18 | 30 | 68 | 54 | 46 | 47 | 13 | 14 | 16 | 26 |
| 18 | 17 | 7 | 2 | 24 | 20 | 18 | 18 | -9 | -7 | 4 | 0 |
|
Growth YoY PAT Growth YoY% | -65.3 | -40.5 | 24.1 | -0.3 | 82.6 | -10.4 | 162.3 | 7.8 | -50.9 | -37.7 | -60.8 | -13.3 |
| 3.3 | 5.3 | 1.6 | 3.9 | 5.6 | 4.8 | 3.6 | 3.7 | 3.1 | 3.1 | 1.6 | 3.5 |
| 0.9 | 1.4 | 0.4 | 1.0 | 1.6 | 1.2 | 1.0 | 1.1 | 0.8 | 0.8 | 0.4 | 0.9 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 14.0 | -2.2 | 15.3 | 74.4 | -9.3 | 2.4 | 4.2 | -5.5 |
| 1,224 | 1,415 | 1,421 | 1,552 | 2,716 | 2,552 | 2,609 | 2,706 | 2,644 |
Operating Profit Operating ProfitCr |
| 11.0 | 9.8 | 7.4 | 12.3 | 11.9 | 8.7 | 8.9 | 9.4 | 6.3 |
Other Income Other IncomeCr | 3 | 5 | 30 | 5 | 15 | 12 | 28 | 25 | 14 |
Interest Expense Interest ExpenseCr | 10 | 17 | 14 | 16 | 15 | 11 | 7 | 20 | 25 |
Depreciation DepreciationCr | 31 | 44 | 49 | 47 | 49 | 72 | 107 | 124 | 97 |
| 113 | 98 | 81 | 158 | 318 | 173 | 171 | 161 | 69 |
| 38 | 25 | 11 | 31 | 61 | 48 | 50 | 47 | -11 |
|
| | -4.4 | -3.0 | 80.9 | 101.8 | -51.4 | -3.3 | -5.8 | -29.9 |
| 5.5 | 4.6 | 4.6 | 7.2 | 8.3 | 4.5 | 4.2 | 3.8 | 2.8 |
| 3.0 | 2.9 | 2.9 | 5.6 | 9.7 | 4.7 | 4.5 | 4.1 | 2.9 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 10 | 50 | 45 | 53 | 53 | 53 | 55 | 55 | 55 |
| 369 | 400 | 382 | 982 | 1,248 | 1,359 | 1,742 | 1,851 | 1,873 |
Current Liabilities Current LiabilitiesCr | 431 | 460 | 529 | 768 | 932 | 830 | 891 | 1,052 | 1,114 |
Non Current Liabilities Non Current LiabilitiesCr | 84 | 105 | 113 | 35 | 34 | 170 | 138 | 85 | 153 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 544 | 625 | 639 | 1,305 | 1,473 | 1,217 | 1,477 | 1,411 | 1,213 |
Non Current Assets Non Current AssetsCr | 351 | 390 | 431 | 533 | 795 | 1,195 | 1,350 | 1,634 | 1,983 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | -7 | 188 | 196 | 106 | 46 | 199 | 561 | 108 |
Investing Cash Flow Investing Cash FlowCr | -85 | -123 | -56 | -641 | 74 | -384 | -490 | -268 |
Financing Cash Flow Financing Cash FlowCr | 85 | -63 | -123 | 527 | -124 | 232 | -42 | 90 |
|
Free Cash Flow Free Cash FlowCr | -7 | 188 | 196 | 106 | 47 | 199 | 561 | 108 |
| -8.9 | 259.2 | 278.4 | 83.5 | 17.8 | 159.7 | 465.7 | 95.1 |
CFO To EBITDA CFO To EBITDA% | -4.5 | 122.4 | 172.2 | 49.0 | 12.4 | 81.4 | 219.5 | 38.6 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 4,594 | 10,533 | 5,908 | 6,491 | 4,856 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 36.1 | 41.1 | 47.4 | 53.9 | 42.8 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.0 | 2.6 | 3.4 | 2.1 | 2.3 | 1.6 |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 4.4 | 8.1 | 4.2 | 3.6 | 2.5 |
| 1.2 | 0.6 | 0.8 | 19.4 | 28.5 | 25.3 | 24.7 | 17.9 |
Profitability Ratios Profitability Ratios |
| 29.6 | 30.1 | 28.9 | 33.6 | 31.5 | 33.7 | 32.8 | 34.8 |
| 11.0 | 9.8 | 7.4 | 12.3 | 11.9 | 8.7 | 8.9 | 9.4 |
| 5.5 | 4.6 | 4.6 | 7.2 | 8.3 | 4.5 | 4.2 | 3.8 |
| 21.6 | 19.4 | 17.2 | 14.8 | 23.1 | 10.1 | 9.1 | 8.4 |
| 20.0 | 16.1 | 16.4 | 12.3 | 19.7 | 8.8 | 6.7 | 6.0 |
| 8.5 | 7.1 | 6.6 | 6.9 | 11.3 | 5.2 | 4.3 | 3.7 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
#### **Overview**
Laxmi Organic Industries Ltd (LOIL), incorporated in 1989, is a leading Indian manufacturer of **Essential and Specialty Chemical Intermediates**, with a growing footprint in the global **fluorospecialties** space. It operates two core business segments:
- **Essentials (Acetyl Intermediates)**: Lean, scale-driven supplier of large-volume industrial chemicals.
- **Specialties (Specialty & Fluoro Intermediates)**: Innovation-led, high-margin segment focusing on complex chemistries and customized solutions.
The company serves 750+ active customers across **55+ countries**, with a strong presence in pharmaceuticals, agrochemicals, paints & coatings, packaging, and high-performance materials. LOIL is evolving from a commodity chemical producer to a **technology-driven specialty chemicals leader**, underpinned by strategic acquisitions, robust R&D, and deep customer integration.
---
### **Strategic Outlook (Nov 2025)**
#### **1. Market Position & Growth Strategy**
- **Diketene Derivatives Market**: LOIL holds an **8–9% global market share** and is the largest product portfolio holder in this segment. It offers **over 40 diketene derivatives**, with 53% revenue share in India (2022–23 data).
- **Fluorospecialties Expansion**:
- LOIL is ramping up its fluorospecialties business post the **Miteni acquisition (2020)** from Italy, leveraging **electrochemical fluorination (ECF) technology**—a first in India.
- The fluorination platform targets a **$2.5 billion global niche** within the broader $25 billion fluorination market, excluding commoditized segments like refrigerants and surfactants.
- Revenues from fluorospecialties are expected to reach **40–50% of peak projections** in 2025, with full commercial ramp-up targeted by FY27–FY28.
- **New Product Innovation**: Over **20% of revenue** is derived from products launched in the past five years, signaling a strong innovation pipeline and market responsiveness.
#### **2. Key Strategic Initiatives and Projects**
- **Hitachi Energy Partnership**:
- A contract has been secured to produce **eco-efficient gas** for Hitachi’s **SF6-free high-voltage switchgear (EconiQ™)**.
- Commercial production is underway in FY25, with capex covered under the **INR 1,100 crore consolidated investment plan**.
- This project enhances LOIL’s positioning in sustainable power transmission and strengthens strategic partnerships with global leaders.
- **Dahej Expansion (Greenfield Site)**:
- A **70 KTA world-scale n-Butyl Acetate plant** is under development at the **86-acre Dahej (Gujarat)** site, designed for economies of scale and export readiness.
- The new facility will **double ketene/diketene capacity** and serve North India and export markets.
- Revenue contribution from Dahej is expected from **H2 FY26**, reaching peak levels by FY28.
- **Lote Fluoro Intermediates Plant**:
- Commercial production began in Q4 FY25, with 16 product approvals from customers.
- The site can support up to **INR 400 crores** of future fluorine-related capex.
#### **3. Innovation and R&D**
- **R&D Infrastructure**:
- LOIL operates a **30,000 sq. ft. Innovation Centre in Mahape, Navi Mumbai** (inaugurated Feb 2025), alongside a **2,500 sq. ft. R&D site in Mahad**.
- Total R&D spend: **~2% of Specialties revenue**, with 15% of employees dedicated to R&D.
- The team includes **67 chemists and 40+ engineers**, supported by kilo labs and pilot plants (100–1,800L reactor scale).
- **Technology Platforms**:
- Commercial-scale platforms in **diketene, ketene, ethylene oxide, mercaptans, and fluorination (ECF & HF)**.
- Notable achievements:
- Redesigned synthesis of a **pharma raw material**, improving end-product purity.
- Scaled up **mercaptan chemistry** for a leading agrochemical innovator.
- Developed **ethyl oxide derivatives** from lab to commercial scale for a global customer.
- **Sustainability Focus**:
- Offers **biobased Ethyl Acetate** with USDA Certified Biobased Product label.
- **25% of power** comes from green sources (hydro, wind, solar).
#### **4. Financial and Operational Highlights (FY25)**
- **Revenue**: **INR 29.85 billion** in FY25.
- **Growth Metrics**:
- **11% volume growth** and **9.4% YoY EBITDA growth** driven by operational excellence and mix optimization.
- **10%+ revenue growth** in Specialties, outpacing volume due to favorable mix and pricing.
- **Cost Leadership**:
- Operates at **full capacity** across assets; **top quartile on global cost curve** for Ethyl Acetate production.
- Achieved **best-in-cost positioning** via scale, efficient logistics, and captive utilities.
- **Capacity Expansion**:
- **World’s first 70 KTA n-Butyl Acetate plant in India** being commissioned at Dahej (Q1 FY26).
- **n-Propyl Acetate** (25 KTA) soft-launched from Mahad—100% import substitute.
- **Balance Sheet & Capex**:
- Unleveraged balance sheet enables future investments.
- **INR 5,500–11,000 crore capex** planned between FY24–FY28 to:
- Double revenue by **FY28**
- Triple EBITDA
- Achieve **20% RoCE**
---
### **Leadership & Organizational Strengths**
- **Dr. Harsh Goenka (Promoter & Strategic Leader)**:
- Led pivot from commodity to **specialty chemicals**, focusing on innovation, M&A, and sustainable value chains.
- Advocate for **India’s self-reliance** in specialty chemicals.
- **Core Management Team**:
- **Salil Mukundan (CTO)**: 34 years in pharma/chemicals (IIT Bombay alum).
- **Rajesh Naik (President - Manufacturing)**: 30 years, ex-BASF, DuPont; leading operational excellence.
- **Susheel Mittal (CSO)**: 25+ years in global supply chains.
- **Dr. Milind Vaidya (EVP - R&D & Specialties)**: 25+ years in R&D and market development.
- **Global Structure**: Subsidiaries in **Europe (Netherlands), China, UAE, and USA**, enhancing export logistics and customer proximity.
---
### **Competitive Advantages**
- **Technology Leadership**: Electrochemical fluorination, continuous fluorination, and proprietary diketene pathways.
- **Scale & Integration**:
- Backward integration via **two ethanol distilleries (Satara, Kolhapur)** and **co-gen power plants**.
- Shared raw materials (acetic acid), infrastructure, and customer base across Essentials and Specialties.
- **Customer-Centric Approach**:
- Shift to **value chain integrator** and **custom solutions model**, increasing wallet share.
- Reduced top-10 customer concentration to **26%**, indicating diversification.
- **Operational Excellence**:
- Use of **data analytics** to improve throughput; **operational efficiency** initiative delivering double-digit volume growth.
- **Responsible Care Certified** and ISO-compliant sites (Mahad, Lote, Dahej).
---
### **Global Market Dynamics & Opportunities**
- **Export Focus**: 30% of revenue from exports (mainly Europe, Middle East, Africa); **strategic storage in Rotterdam** for faster delivery.
- **China+1 Tailwinds**: Global supply chain shifts are accelerating demand for Indian-made specialty chemicals.
- **Fluorochemical Demand Drivers**:
- Fluorine present in **1 in 3 new APIs** and **50% of new agrochemicals**.
- Strong customer pull for **import-substituted fluoro-chemicals**, reducing foreign exchange exposure.
- **Sustainability Shift**: Demand for **green solvents** and **SF6-free gas alternatives** aligns with LOIL’s offerings.